Machine signal
Active cluster sell — 7 distinct insiders, $32.5M, window ends Sep 14, 2026.
Figures computed from official regulatory filings — .
Analysttarget 138.59 USD (+49%) · consensus 4.5/5 · 16 buy · 2 hold · 0 sell
Ownershipinsiders 0.7% · institutions 114.84% · short 15.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for RHYTHM PHARMACEUTICALS, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
20 buys314 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Meeker David P | Exercise | $302.5K | SEC |
| Meeker David P | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Meeker David P | Sell | $899.6K | SEC |
| Meeker David P | Sell | $241.9K | SEC |
| Meeker David P | Sell | $190K | SEC |
| Meeker David P | Sell | $3.1M | Unusual size | SEC |
| Meeker David P | Sell | $655.1K | SEC |
| Smith Hunter C | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Smith Hunter C | Sell | $2.4M | Unusual size | SEC |
| Smith Hunter C | Sell | $3M | Unusual size | SEC |
| Smith Hunter C | Exercise | $1.5M | Unusual size | SEC |
| Smith Hunter C | Sell | $1.2M | Unusual size | SEC |
| Joshi Manher | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Joshi Manher | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Garfield Alastair | Sell | $233K | SEC |
| Garfield Alastair | Sell | $402.2K | SEC |
| Garfield Alastair | Sell | $182.2K | SEC |
| Shulman Joseph | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shulman Joseph | Sell | $608.2K | SEC |
| Garfield Alastair | Sell | $95.3K | SEC |
| Shulman Joseph | Exercise | $13.8K | SEC |
| Mazabraud Yann | Sell | $112.9K | SEC |
| Mazabraud Yann | Sell | $257.1K | SEC |
| Mazabraud Yann | Sell | $413.5K | SEC |
| Chien Jennifer | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |